The human brain is highly skilled at detecting patterns in the world and using this information to predict future events. This ability to anticipate events is also reflected in how we experience music ...
WASHINGTON, DC—In patients with right ventricular outflow tract (RVOT) conduit dysfunction, transcatheter pulmonary valve (TPV) replacement demonstrates high procedural success, excellent short-term ...
Palatin Technologies, Inc. PTN announced that it has initiated the pivotal phase III MELODY-1 study evaluating its melanocortin agonist, PL9643, for the treatment of patients with dry eye disease ...
MINNEAPOLIS and WASHINGTON - March 30, 2014 - Medtronic, Inc. (MDT), today announced the one-year results of the Melody ® Transcatheter Pulmonary Valve (TPV) U.S. Post-Approval Study, which found that ...
Please provide your email address to receive an email when new articles are posted on . WASHINGTON — The Melody Transcatheter Pulmonary Valve led to excellent hemodynamic function at 6 months, along ...
Palatin Technologies, Inc., a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, ...
The MELODY study, officially known as "MELODY - MEthods for LOcalization of Different types of breast lesions," is a prospective, international, non-interventional multicenter cohort study. It focuses ...
NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. This is an ASCO Meeting Abstract ...
Palatin Technologies, Inc. PTN announced that it has initiated the pivotal phase III MELODY-1 study evaluating its melanocortin agonist, PL9643, for the treatment of patients with dry eye disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results